NYSE:BIO - Bio-Rad Laboratories Stock Price, News & Analysis

$342.18
+3.84 (+1.13 %)
(As of 09/19/2019 01:32 PM ET)
Today's Range
$338.26
Now: $342.18
$343.98
50-Day Range
$313.55
MA: $331.29
$343.74
52-Week Range
$220.05
Now: $342.18
$345.50
Volume2,105 shs
Average Volume181,578 shs
Market Capitalization$10.20 billion
P/E Ratio58.71
Dividend YieldN/A
Beta1.18
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 billion
Cash Flow$6.0713 per share
Book Value$134.91 per share

Profitability

Net Income$365.61 million

Miscellaneous

Employees8,260
Market Cap$10.20 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its Board of Directors has approved a stock buyback program on Wednesday, November 29th 2017, which allows the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings data on Thursday, August, 1st. The medical research company reported $1.57 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.39 by $0.18. The medical research company had revenue of $572.60 million for the quarter, compared to the consensus estimate of $564.88 million. Bio-Rad Laboratories had a net margin of 39.32% and a return on equity of 3.92%. The business's revenue was down .6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.64 EPS. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Bio-Rad Laboratories.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.38171336-2.393163905 billion, compared to the consensus revenue estimate of $2.35 billion.

What price target have analysts set for BIO?

5 brokerages have issued 1 year target prices for Bio-Rad Laboratories' stock. Their predictions range from $335.00 to $420.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $382.00 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

What are Wall Street analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:
  • 1. According to Zacks Investment Research, "Over the past year, Bio-Rad has outperformed its industry. We are encouraged with the year-over-year rise in earnings in the last-reported quarter. Constant currency sales growth at the Clinical Diagnostics segment was impressive. The company also saw strong growth in the Life Science segment and cell biology, droplet Digital PCR, gene expression and antibody product lines. Further, solid revenue growth in geographies like Americas and Asia Pacific buoys optimism. We are also upbeat about the company’s receipt of FDA approval for the QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit.  However, challenges associated with the implementation of the global ERP system raise concerns. Further, Bio-Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates." (5/1/2019)
  • 2. Jefferies Financial Group Inc analysts commented, "We see substantial hidden value in BIO’s droplet digital PCR (ddPCR) franchise that is under-appreciated by investors." (9/24/2018)

Has Bio-Rad Laboratories been receiving favorable news coverage?

Headlines about BIO stock have trended negative on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Bio-Rad Laboratories.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 552,800 shares, an increase of 14.7% from the July 31st total of 482,100 shares. Based on an average daily trading volume, of 181,400 shares, the short-interest ratio is presently 3.0 days. Currently, 2.6% of the shares of the stock are short sold. View Bio-Rad Laboratories' Current Options Chain.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), First Solar (FSLR), Dynavax Technologies (DVAX), Celgene (CELG), ImmunoGen (IMGN), Array Biopharma (ARRY) and Exelixis (EXEL).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.55%), BlackRock Inc. (6.55%), Vanguard Group Inc. (6.39%), Atlanta Capital Management Co. L L C (2.54%), Russell Investments Group Ltd. (1.38%) and UBS Asset Management Americas Inc. (1.33%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, AQR Capital Management LLC, Cibc World Markets Corp, Hoplite Capital Management L.P., BNP Paribas Arbitrage SA, Canada Pension Plan Investment Board, Citadel Advisors LLC and Fort Washington Investment Advisors Inc. OH. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Insider Buying and Selling for Bio-Rad Laboratories.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Invesco Ltd., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Nuveen Asset Management LLC, Prudential Financial Inc., WINTON GROUP Ltd and Tamarack Advisers LP. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $342.18.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $10.20 billion and generates $2.29 billion in revenue each year. The medical research company earns $365.61 million in net income (profit) each year or $5.84 on an earnings per share basis. Bio-Rad Laboratories employs 8,260 workers across the globe.View Additional Information About Bio-Rad Laboratories.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com/.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  616
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel